Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® and $23.9 million for EMPAVELI® SYFOVRE showed continued strong demand with growth.
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.
At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.